tegafur has been researched along with Hyperpigmentation in 5 studies
Hyperpigmentation: Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.
Excerpt | Relevance | Reference |
---|---|---|
"5 mg/kg/day regimen produced one dead or moribund dog of each sex; black-brown patch (melanin deposition) and inflammatory changes in the eyes and skin; decreased in body weight gains; increases in MCV, MCH, monocyte ratio, and serum protein and uric acid; decreases in lymphocyte ratio and erythrocyte count, hematocrit, hemoglobin, albumin, A/G ratio, cholesterol (esterified, total and free), phospholipids, triglycerides, cholinesterase activity and creatinine; increases in relative liver and adrenal weights." | 3.69 | [A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs]. ( Enomoto, M; Inoue, H; Kitajima, S; Kobayashi, K; Okamura, T; Watari, N; Yamaguchi, S, 1996) |
"Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited." | 2.84 | S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial. ( Date, Y; Fang, X; Furuse, J; Hidaka, H; Ikeda, M; Kaneko, S; Kawazoe, S; Kudo, M; Moriguchi, M; Numata, K; Ohkawa, S; Okusaka, T; Sato, Y; Takeuchi, M; Tanaka, H, 2017) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (60.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kudo, M | 1 |
Moriguchi, M | 1 |
Numata, K | 1 |
Hidaka, H | 1 |
Tanaka, H | 1 |
Ikeda, M | 1 |
Kawazoe, S | 1 |
Ohkawa, S | 1 |
Sato, Y | 1 |
Kaneko, S | 1 |
Furuse, J | 1 |
Takeuchi, M | 2 |
Fang, X | 1 |
Date, Y | 1 |
Okusaka, T | 1 |
Kim, HS | 1 |
Park, YM | 1 |
Kim, HO | 1 |
Lee, JY | 1 |
Kitajima, S | 1 |
Okamura, T | 1 |
Kobayashi, K | 1 |
Watari, N | 1 |
Inoue, H | 1 |
Enomoto, M | 1 |
Yamaguchi, S | 1 |
Rios-Buceta, L | 1 |
Buezo, GF | 1 |
PeƱas, PF | 1 |
Dauden, E | 1 |
Fernandez-Herrera, J | 1 |
Garcia-Diez, A | 1 |
Revenga, F | 1 |
1 trial available for tegafur and Hyperpigmentation
Article | Year |
---|---|
S-1 versus placebo in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Diarrhea; Double-Blind Method; Dru | 2017 |
4 other studies available for tegafur and Hyperpigmentation
Article | Year |
---|---|
Tegafur-induced hyperpigmentation of the tongue.
Topics: Adult; Antimetabolites, Antineoplastic; Female; Humans; Hyperpigmentation; Stomach Neoplasms; Tegafu | 2010 |
[A 52-week oral toxicity study of a new antineoplastic agent S-1 in dogs].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Blood Coagu | 1996 |
Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Erythema; Female; Foot Dermatoses; Hand Dermatoses; | 1997 |
Cutaneous side-effects caused by Tegafur.
Topics: Aged; Antimetabolites, Antineoplastic; Drug Eruptions; Female; Humans; Hyperpigmentation; Male; Phot | 1999 |